Not sure where this fear is originating from but I'll not complaining. You know this is setting up well as a great opportunity into earnings on April 20th
Gilead Sciences (NASDAQ:GILD) was upgraded by investment analysts at Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday. The firm currently has a $110.67 target price on the stock. Vetr‘s price target suggests a potentialupside of 12.77% from the company’s current price.
Won't get that low this close to earnings. All the pros have done the math from the script numbers and know an easy beat and raised guidance is coming.
Low conservative yearly guidance that was set last ER will be increased as US Scripts are far above expectations with increased vsales volume more than making up for increased discounts, Europe sales doing better then expected (although weak Euro is not helping) and Japan approving Sovaldi months earlier then expected. I think this current dip will be bought and we'll see a rally into earnings.
They need to make this kit generic to monetarily capitalize on this invention. May bring in as much revenue as the drugs?
PE of 10 in a growing biotech is very cheap. Everyone keeps saying how Gilead is cheap and it's PE is 13.5. This stock has much more to run.
So I guess everything comes down to Phase III results. Personally I don't know the chances of whether results are good or not. Based on the PR I understood Cipher doesn't pay a cent until US approval. Am I wrong on that?? If they are paying $1M up front regardless then they must be very confident of approval and of which I would considering investing, otherwise it's a binary event and you might as well bet you rmoney on a roulette table.
If CELG is cheap then I guess GILD is free at about 1/4 of the PE. I do own both but expect that GILD has more upside at this point as this has run the last 6 monthe whereas GILD hasn't.
If every stock ran to analyist's target then we'd all be rich. Anyone else knwo their plan for making revenue and/or raising funds before they run out of money?
According to Yahoo they have $3.8M in cash and their presentation says their burn rate is $440K per months. So they basically only have 8 months before they are broke. Does anyone know their plans to make or raise funds? It sucks being caught in a stock when they announce a note or debt offering.
GILD is a no brainer at this point and into earnings as they will easily beat estimate and raise guidence.
I would cover your short in premarket while it is still under $100. Japan approval news today will lift this over $101 and higher today. MM's like premarket to be down as a starting point for accumulation.
Should trump any market sell off as this is big news. Guidence will be increased in April 20 earnings call.
Great news! I thought this wasn't expected until the summer. Now GILD can raise guidence in next earnings release. This combined with Canadian providing as part of gov't provided health care and Europe approvals will bring in huge numbers that are not part of weekly script numbers.
Cipher has a complimentary drug that is currently awaiting appoval so they are deeply aware of the Fed approval pipeline and which drugs are of most value.
Hope you're right as I'll be in buying more at this last chance under $98 sale before blow out earnings runup. GILD has a lot of catching up to do versus bio index now that they have proven that there isn't any worthy competition, and scripts are beating all estimates.
Can't help but notice this stock hitting year highs while everything else is tanking. Something is in the works!!